You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Initial bromocriptine did not change mortality in early, mild Parkinson's disease

https://doi.org/10.1136/ebm.7.3.91

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) Neurology 57, 1687. Lees AJ, Katzenschlager R, Head J, et al, on behalf of the Parkinson's Disease Research Group of the United Kingdom.. Ten-year follow-up of three different initial treatments in de-novo PD. A randomized trial.. Nov 13;. :. –94.
    OpenUrlAbstract/FREE Full Text

    
 
 QUESTION: In patients with early, mild Parkinson's disease (PD), does the long term effectiveness of levodopa alone differ from that of levodopa plus selegiline or initial bromocriptine monotherapy?

    Design

    Randomised {allocation concealed*}†, blinded {data safety and monitoring committee}†,* controlled trial with a mean 9.2 years of follow up.

    Setting

    UK.

    Patients

    782 patients with a clinical diagnosis of PD. Exclusion criteria were failure to respond to an adequate trial of dopaminergic drugs or incapacitating cognitive impairment.

    Intervention

    249 patients were allocated to levodopa alone, 271 to levodopa plus selegiline, and 262 to initial bromocriptine. 104 patients in the bromocriptine group were rerandomised to 1 of the other 2 treatment groups after bromocriptine was withdrawn, but all patients were analysed in the groups to which they were initially randomised.

    Main outcome measures

    Mortality, disability, and adverse effects. …

    View Full Text